Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oseltamivir.

A Bardsley-Elliot1, S Noble

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|December 14, 1999
PubMed
Summary
This summary is machine-generated.

Oseltamivir effectively treats and prevents influenza A and B by inhibiting viral neuraminidase. This antiviral medication is well-tolerated, with low resistance rates observed in clinical studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Virology
  • Pharmacology
  • Infectious Diseases

Background:

  • Oseltamivir is an oral prodrug converted to GS4071, a selective inhibitor of influenza A and B viral neuraminidase.
  • GS4071 achieves high plasma concentrations and distributes effectively to respiratory tissues.
  • Influenza remains a significant public health concern, necessitating effective treatment and prevention strategies.

Purpose of the Study:

  • To evaluate the efficacy and safety of oseltamivir in treating naturally occurring influenza.
  • To assess the prophylactic effectiveness of oseltamivir in preventing influenza illness.
  • To determine the incidence of viral resistance to GS4071 during oseltamivir treatment.

Main Methods:

  • Two large placebo-controlled, double-blind trials were conducted for treatment efficacy.

Related Experiment Videos

  • Two large placebo-controlled, double-blind trials in volunteers assessed prophylactic use.
  • Clinical isolates from treatment studies were analyzed for viral resistance to GS4071.

    • Main Results:

    • Oseltamivir significantly reduced influenza symptom duration and severity when given within 36 hours of onset.
    • Prophylactic oseltamivir effectively lowered the incidence of influenza illness in healthy volunteers.
    • Viral resistance to GS4071 was low, with resistant genotypes showing reduced infectivity.

    Conclusions:

    • Oseltamivir is an effective treatment for influenza, reducing symptoms and complications.
    • Oral oseltamivir provides effective prophylaxis against seasonal influenza.
    • The drug is well-tolerated, with mild and transient gastrointestinal side effects being most common.